RCI
CLDI icon

RS Crum Inc’s Calidi Biotherapeutics CLDI Stock Holding History

RS Crum Inc’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.61K Buy
40,256
+20,000
+99% +$15K ﹤0.01% 102
2025
Q4 		$23.7K Buy
20,256
+5,000
+33% +$7.36K ﹤0.01% 97
2025
Q3 		$23.2K Buy
+15,256
New +$64.8K 0.01% 99
2025
Q2 		– Sell
-4,609
Closed -$31.3K – 92
2025
Q1 		$31.3K Buy
4,609
+1,237
+37% +$14.1K 0.01% 88
2024
Q4 		$46.5K Buy
+3,372
New +$63.2K 0.01% 90
2024
Q3 		– Sell
-2,196
Closed -$52.7K – 96
2024
Q2 		$52.7K Buy
2,196
+2,106
+2,340% +$67.3K 0.01% 92
2024
Q1 		$6.13K Buy
+90
New +$9.19K ﹤0.01% 81

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return

RS Crum Inc's CLDI Position: Q1 2026 in Review

RS Crum Inc increased its Calidi Biotherapeutics (CLDI) stake by 99% in Q1 2026, buying an estimated $15K and bringing the position to 40,256 shares worth $9.61K. The position accounts for ﹤0.01% of the portfolio, ranked #102.

RS Crum Inc first reported a position in CLDI in Q1 2024 and has held it in 7 quarters since. The position peaked at $52.7K in Q2 2024. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

  • RS Crum Inc held 40,256 shares of Calidi Biotherapeutics worth $9.61K as of Q1 2026.
  • RS Crum Inc bought 20,000 Calidi Biotherapeutics shares in Q1 2026, an estimated $15K.
  • Calidi Biotherapeutics made up ﹤0.01% of RS Crum Inc's portfolio in Q1 2026, its #102 holding.
  • RS Crum Inc first reported a position in Calidi Biotherapeutics in Q1 2024 and has held it in 7 quarters since.
  • RS Crum Inc's Calidi Biotherapeutics position peaked at $52.7K in Q2 2024.
  • 28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on RS Crum Inc's 13F filing for Q1 2026, filed 15 Apr 2026.